 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ZN-e4 / Zentalis Pharma
Phase classification, Metastases: A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 24, 2024
P1, N=34, Completed, Sponsor: Zeno Pharmaceuticals, Inc.
Phase classification: P1/2 --> P1
- || ZN-e4 / Zentalis Pharma
Trial completion, Metastases: A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 6, 2022
P1/2, N=34, Completed, Sponsor: Zeno Pharmaceuticals, Inc.
Phase classification: P1/2 --> P1 Active, not recruiting --> Completed
- ||| ZN-e4 / Zentalis Pharma
Enrollment change, Trial primary completion date, Metastases: A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 15, 2022
P1/2, N=34, Active, not recruiting, Sponsor: Zeno Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=140 --> 34 | Trial primary completion date: Jun 2022 --> Jan 2022
- || ZN-e4 / Zentalis Pharma
Enrollment closed, Metastases: A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 4, 2022
P1/2, N=140, Active, not recruiting, Sponsor: Zeno Pharmaceuticals, Inc.
N=140 --> 34 | Trial primary completion date: Jun 2022 --> Jan 2022 Recruiting --> Active, not recruiting
- KP-673 / SciClone, Zentalis Pharma
[VIRTUAL] Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer () - Mar 11, 2021 - Abstract #AACR2021AACR_1660;
Taken together, our data suggest that ZN-e4 is a potent and selective third generation EGFR inhibitor. Currently, ZN-e4 is in a Phase I clinical trial in patients with EGFR mutant NSCLC showing clinical activity and encouraging toxicity profile.
- KP-673 / SciClone, Zenopharm
Zn-e4 (STARLIGHT BALLROOM) - Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_50;
- | ZN-e4 / Zentalis Pharma
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 23, 2019
P1/2, N=140, Recruiting, Sponsor: Zeno Pharmaceuticals, Inc.
Currently, ZN-e4 is in a Phase I clinical trial in patients with EGFR mutant NSCLC showing clinical activity and encouraging toxicity profile. Phase classification: P1 --> P1/2 | N=100 --> 140 | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Mar 2020 --> Jun 2022
- | ZN-e4 / Zentalis Pharma
New P1 trial, Metastases: A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 11, 2019
P1, N=100, Not yet recruiting, Sponsor: Zeno Pharmaceuticals, Inc.
- | ZN-e4 / Zentalis Pharma
Enrollment open, Metastases: A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 28, 2018
P1, N=100, Recruiting, Sponsor: Zeno Pharmaceuticals, Inc.
Phase classification: P1 --> P1/2 | N=100 --> 140 | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Mar 2020 --> Jun 2022 Not yet recruiting --> Recruiting